WallStreetZen

NYSE: NVS
Novartis Ag Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for NVS

Based on 3 analysts offering 12 month price targets for Novartis Ag.
Min Forecast
$109.00+12.51%
Avg Forecast
$110.50+14.06%
Max Forecast
$112.50+16.12%

Should I buy or sell NVS stock?

Strong Buy
Strong Buy
7 analysts 77.78%
Buy
0 analysts 0%
Hold
1 analysts 11.11%
Sell
0 analysts 0%
Strong Sell
1 analysts 11.11%

Forecast return on equity

Is NVS forecast to generate an efficient return?
Company
32.79%
Industry
75.15%
Market
62.3%
NVS's Return on Equity is forecast to be high in 4 years (32.79%); analysts are confident in the firm's ability to efficiently generate return on equity
Forecast

Forecast return on assets

Is NVS forecast to generate an efficient return on assets?
Company
15.37%
Industry
16.93%
Market
19.84%
NVS is forecast to generate lower Return on Assets (15.37%) than the US Drug Manufacturers - General industry average (16.93%)
Forecast

NVS earnings per share forecast

What is NVS's earnings per share in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
$6.52+27.27%
Avg 2 year Forecast
$7.08+38.18%
Avg 3 year Forecast
$7.51+46.68%
NVS's earnings are forecast to grow at a rate of 13.82% per year, which is not exceptional
Forecast

NVS revenue forecast

What is NVS's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$53.6B+10.1%
Avg 2 year Forecast
$55.8B+14.72%
Avg 3 year Forecast
$58.7B+20.62%
NVS's revenue is forecast to grow at a rate of 6.34% per year, which is not exceptional
Forecast

NVS earnings growth forecast

How is NVS forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
13.82%
Industry
25.09%
Market
20.63%
NVS's earnings are forecast to grow slower (13.82% per year) than the US Drug Manufacturers - General industry average (25.09%)
Forecast
NVS's earnings are forecast to grow slower (13.82% per year) than the US market average (20.63%)
Forecast
NVS's earnings are forecast to grow faster (13.82% per year) than the risk-free savings rate (1.1%)
Forecast

NVS revenue growth forecast

How is NVS forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
6.34%
Industry
6.43%
Market
14.47%
NVS's revenues are forecast to grow slower (6.34% per year) than the US Drug Manufacturers - General industry average (6.43%)
Forecast
NVS's revenues are forecast to grow slower (6.34% per year) than the US market average (14.47%)
Forecast

Novartis Ag Stock Forecast FAQ

Is Novartis Ag Stock a good buy in 2019, according to Wall Street analysts?

The consensus among 9 Wall Street analysts covering (NYSE: NVS) stock is to Strong Buy NVS stock.

Out of 9 analysts, 7 (77.78%) are recommending NVS as a Strong Buy, 0 (0%) are recommending NVS as a Buy, 1 (11.11%) are recommending NVS as a Hold, 0 (0%) are recommending NVS as a Sell, and 1 (11.11%) are recommending NVS as a Strong Sell.

What is NVS's Price Target?

According to 3 Wall Street analysts that have issued a 1 year NVS price target, the average NVS price target is $110.50, with the highest NVS stock price forecast at $112.50 and the lowest NVS stock price forecast at $109.00.

On average, Wall Street analysts predict that Novartis Ag's share price could reach $110.50 by Jan 20, 2022. The average Novartis Ag stock price prediction forecasts a potential upside of 14.06% from the current NVS share price of $96.88.

What is NVS's earnings growth forecast for 2021-2023?

(NYSE: NVS) Novartis Ag's forecast annual earnings growth rate of 13.82% is not forecast to beat the US Drug Manufacturers - General industry's average forecast earnings growth rate of 25.09%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 20.63%.

Novartis Ag's earnings in 2019 is $11,732,000,000.On average, 5 Wall Street analysts forecast NVS's earnings for 2021 to be $15,059,593,031, with the lowest NVS earnings forecast at $14,791,497,146, and the highest NVS earnings forecast at $15,230,619,717. On average, 2 Wall Street analysts forecast NVS's earnings for 2022 to be $16,351,537,860, with the lowest NVS earnings forecast at $16,131,976,574, and the highest NVS earnings forecast at $16,571,099,146.

In 2023, NVS is forecast to generate $17,356,897,432 in earnings, with the lowest earnings forecast at $17,356,897,432 and the highest earnings forecast at $17,356,897,432.

What is NVS's revenue growth forecast for 2021-2023?

(NYSE: NVS) Novartis Ag's forecast annual revenue growth rate of 6.34% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.43%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.47%.

Novartis Ag's revenue in 2019 is $48,677,000,000.On average, 2 Wall Street analysts forecast NVS's revenue for 2021 to be $123,861,420,141,111, with the lowest NVS revenue forecast at $122,843,314,459,065, and the highest NVS revenue forecast at $124,879,525,823,157. On average, 2 Wall Street analysts forecast NVS's revenue for 2022 to be $129,063,578,131,361, with the lowest NVS revenue forecast at $126,658,480,695,487, and the highest NVS revenue forecast at $131,468,675,567,236.

In 2023, NVS is forecast to generate $135,702,741,625,164 in revenue, with the lowest revenue forecast at $135,702,741,625,164 and the highest revenue forecast at $135,702,741,625,164.

What is NVS's Earnings Per Share (EPS) forecast for 2021-2023?

(NYSE: NVS) Novartis Ag's current Earnings Per Share (EPS) is $5.12. On average, analysts forecast that NVS's EPS will be $6.52 for 2021, with the lowest EPS forecast at $6.40, and the highest EPS forecast at $6.59. On average, analysts forecast that NVS's EPS will be $7.08 for 2022, with the lowest EPS forecast at $6.98, and the highest EPS forecast at $7.17. In 2023, NVS's EPS is forecast to hit $7.51 (min: $7.51, max: $7.51).

What is NVS's forecast return on equity (ROE) for 2021-2024?

(NYSE: NVS) forecast ROE is 32.79%, which is considered strong.

What is NVS's forecast return on assets (ROA) for 2021-2024?

(NYSE: NVS) forecast ROA is 15.37%, which is lower than the forecast US Drug Manufacturers - General industry average of 16.93%.
WallStreetZen
©2021 WallStreetZen
Company
AboutBlogPrivacy PolicyTerms of ServiceContact
Stocks
Stock ScreenerStock ForecastHighest Earnings StocksBest Dividend Paying StocksStatistics
Social
TwitterYouTube
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Heap | Mobile and Web Analytics